1. Wilens TE, Bierderman J, Spencer TJ. Attention deficit/hyperactivity disorder across the lifespan. Ann Rev Med 2002;53:113-131. PMID:
11818466.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 1994,Washington DC: American Psychiatric Association.
3. Barkley R, Fischer M, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1990;29:546-557. PMID:
2387789.
4. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993;50:565-576. PMID:
8317950.
5. Lilienfeld S, Waldman ID. The relation between childhood attention-deficit hyperactivity disorder and adult antisocial behavior reexamined: the problem of heterogeneoity. Clin Psychol Rev 1990;10:699-725.
6. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41(2 Suppl):26S-49S. PMID:
11833633.
7. Horwitz SM, Kelleher K, Boyce T, Jensen P, Murphy M, Perrin E, et al. Barriers to health care research for children and youth with psychosocial problems. JAMA 2002;288:1508-1512. PMID:
12243638.
8. Hoagwood K, Kelleher KJ, Feil M, Corner DM. Treatment services for children with ADHD: a national perspective. J Am Acad Child Adolesc Psychiatry 2000;39:198-206. PMID:
10673831.
9. Leslie LK, Weckerly J, Landsverk J, Hough RL, Hurlburt MS, Wood PA. Racial/ethnic differences in the use of psychotropic medication in high-risk children and adolescents. J Am Acad Child Adolesc Psychiatry 2003;42:1433-1442. PMID:
14627878.
10. Angold A, Costello EJ, Farmer EM, Burns BJ, Erkanli A. Impaired but undiagnosed. J Am Acad Child Adolesc Psychiatry 1999;38:129-137. PMID:
9951211.
11. Bussing R, Gary FA, Mills TL, Garvan CW. Parental explanatory models of ADHD: gender and cultural variations. Soc Psychiatry Psychiatr Epidemiol 2003;38:563-575. PMID:
14564385.
12. Zwirs BW, Burger H, Buitelaar JK, Schulpen TW. Ethnic differences in parental detection of externalizing disorders. Eur Child Adolesc Psychiatry 2006;15:418-426. PMID:
16685474.
13. Greenhill L. Attention-deficit hyperactivity disorder: the stimulants. Child Adolesc Psychiatr Clin N Am 1995;4:123-168.
14. Service Hira. 2006 Health insurance review & assessment service. 2006,Seoul, Korea.
15. Kim YS, Cheon KA, Kim BN, Chang SA, Yoo HJ, Kim JW, et al. The reliability and validity of Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version-Korean version (K-SADS-PL-K). Yonsei Med J 2004;45:81-89. PMID:
15004873.
16. Swanson J. Remission vs. Response as the Goal of Therapy in ADHD. ADHD forum. 2005,Seoul.
17. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896-1901. PMID:
12411225.
18. So YK, Noh JS, Kim YS, Ko SG, Koh YJ. The relaibility and validity of Korean parent and teacher ADHD rating scale. J Korean Neuropsychiatr Assoc 2002;41:283-289.
19. Kim YS, So YK, Noh JS, Choi NK, Kim SJ, Koh YJ. Normative data on the Korean ADHD Rating Scales(K-ARS) for parents and teacher. J Korean Neuropsychiatr Assoc 2003;42:352-359.
20. Barkley RA, McMurray MB, Edelbrocks CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 1990;86:184-192. PMID:
2196520.
21. Lee SI, Hong SD, Kim SY, Kim EJ, Kim JH, Park MK, et al. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:210-216. PMID:
17046131.
22. Shin JY, Yang JW, Jang WS, Hong SD. Prescription status and efficacy of OROS-MPH and parent perception in children with ADHD: multi-center, observational study during 4 weeks. Korean J Psychopharmacol 2007;18:50-59.
23. Kim BS, Park EJ. An observational multi-center study for evaluation of efficacy, safety and parental satisfaction of methylphenidate-OROS in children with ADHD. J Child Adolesc Psychiatry 2005;16:279-285.
24. Wilens T, Pelham W, Stein M, Conners CK, Abikoff H, Atkins M, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2003;42:424-433. PMID:
12649629.
25. Wigal SB, Gupta S, Greenhill L, Posner K, Lerner M, Steinhoff K, et al. Parmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007;17:153-164. PMID:
17489710.
26. Fallu A, Richard C, Prinzo R, Binder C. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder. Curr Med Res Opin 2006;22:2557-2566. PMID:
17166338.
27. McGough JJ, McBurnett K, Bukstein O, Wilens TE, Greenhill L, Lerner M, et al. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2006;16:351-356. PMID:
16768642.
28. Barkley RA, DuPaul GJ, McMurray MB. Attention deficit disorder with and without hperctivity: clinical response to three dose levels of methylphenidate. Pediatrics 1991;87:519-531. PMID:
2011430.
29. Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003;112:e404PMID:
14595084.
30. Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2006;160:82-90. PMID:
16389216.